初诊多发性骨髓瘤治疗进展浅析.ppt

UPFRONT 研究：VD vs VTD vs VMP 初治不适合移植的骨髓瘤患者随机入3个试验组 入选患者疾病标准: 症状性骨髓瘤, 可测量病变 1° R A N D O M I Z A T I O N VD 8 *21-day courses V 1.3 mg/m2, d 1, 4, 8, 11; D 20 mg, d 1, 2, 4, 5, 8, 9, 11, 12 [cycles 1–4]), d 1, 2, 4, 5 [cycles 5–8] VTD 8* 21-day courses V as before; T 100 mg/day, d 1–21; D as before VMP 8 21-day courses V as before; M 9 mg/m2 ; d 1–4 every other cycle P 60 mg/m2, d 1–4 every other cycle MAINTENANCE five 35-day cycles weekly V 1.6 mg/m2, d 1, 8, 15, 22. The primary endpoint:PFS Ruben Niesvizky, et al.Blood 2013 122:1966 ORR:VD 73% VTD 80% VMP70% CR/nCR 率：